Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 500
- Avg volume
- 5,549
- Day's range
- $0.12 – $0.12
- Shares out
- —
- Stochastic %K
- 18%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. It also focuses on the development, distribution, and sale of over-the...
Show more
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. The company was founded in 2019 and is based in Toronto, Canada.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Phone
- 416-477-1708
- Website
- https://psyence.com
- Address
- 121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
Latest news
No headlines yet.
